Notably, recent studies have tested the immunotherapeutic potential of anti-CXCR2 blockade using AZD5069 alone or in combination in many human cancers including; head and neck (NCT02499328), pancreatic (NCT02583477), prostate (NCT03177187), liver [54] and herein, the thyroid. This evidence concerns the gene CXCR2 and cancer.